Suven Life Sciences Limited

Equities

SUVEN

INE495B01038

Biotechnology & Medical Research

Market Closed - Bombay S.E. Other stock markets 04:37:13 27/05/2024 BST			5-day change	1st Jan Change
100 ^INR	+0.15%		+0.76%	+23.98%

05-06	Suven Life Sciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI
05-06	Suven Life Sciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Suven Life Sciences : Newspaper Advertisements

November 23, 2022 at 09:15 am

November 23, 2022

Listing Department	Listing Department
BSE Limited	National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers	Bandra Kurla Complex
Dalal Street, Fort	Bandra (East)
Mumbai - 400001	Mumbai - 400 051
BSE Scrip Code: 530239	NSE Symbol: SUVEN

Subject: Post Rights Issue Advertisement

Ref.: Intimation under Regulations 92 of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, and Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (SEBI Listing Regulations)

Dear Sir / Madam,

This is further to our intimations dated June 24, 2022, October 12, 2022, October 18, 2022 and November 16, 2022 in relation to the issue of equity shares of face value of ₹ 1 each of the Company on a rights basis to the eligible equity shareholders of the Company in accordance with applicable laws, including the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (SEBI ICDR Regulations) (Issue).

In this regard, we wish to inform that the Company has issued an advertisement under Regulation 92

of the SEBI ICDR Regulations, which includes, inter alia, details relating to subscription, basis of allotment, number, value and percentage of all applications including ASBA, number, value and percentage of successful allottees for all applications including ASBA, date of completion of despatch of refund orders, as applicable, or instructions to self- certified syndicate banks by the Registrar, date of despatch of certificates or date of credit of specified securities, as applicable, and date of filing of listing application, etc.

We enclose copies of Advertisement in 'pdf' format, issued by the Company today i.e. November 23, 2022, in all editions of Financial Express, an English national daily newspaper, all editions of Jansatta, a Hindi national daily newspaper and, Nava Telangana, a Telugu daily newspaper (Telugu being the regional language of Telangana, where the registered office of the Company is located), each with wide circulation, for dissemination on your website.

You are requested to take the above on record.

Thanking you.

Yours faithfully,

For Suven Life Sciences Limited

SHRENIK SONI

Shrenik Soni

Digitally signed by SHRENIK SONI Date: 2022.11.23 13:18:18 +05'30'

Company Secretary

Suven Life Sciences Limited

Registered Office: 8-2-334I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7 Banjara Hills I Hyderabad - 500 034 I Telangana I India I CIN: L24110TG1989PLC009713

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com

2	23	2022
					=	C≤Ø		@sêŒ≥T

					ã÷´s√-
		ã÷´s√ `	Áu≤+∫
	qT+∫			. á	@sêŒ≥T
	.	27q

	.	Ä		qT+∫	C≤Ø	. B+'√	ø√≥-]		ñqï
		.					<√eT˝
	nqTeT‹			n≥T	Á>±e÷T			e#êÃsTT.
	Ç≥T	ø=qkÕ- .
		.	.	12
			.

	ø=qkÕ-			~
		.			˝
	. á
fø√ï	n_		.
.	.

					e÷J	.		O+<>

					. á	Ä»+ ,	>±´Øà		.

								sêJHêe÷
					. á	e÷J eT+Á‹ eTÁ]	Ä	sêJHêe÷
					. á	.. 'êqT

					.	$esê'√
					.	.		.
					.			sêJHêe÷

					.	.			qT+∫

					nìï	e#êÃeTì, nsTTHê	e∫Ãq	bÕ≥T ø=qkÕ-	.
						.

��

��	��
	��
�	� � �
�	� � � � � � �

� � � � �

� � �

�

� � �

��

�

��

�

��

�

��

�

��

�

� � �

� � � � � � � � � � �

� �

�

� �

� � �

�

� �

� ��

��

� �

� � ��

�

� �

�

� �

�

� ��

��

�

��

�

� �

�

� ��

�

� ��

��

�

��

�

��

�

��

�

��

� ��

��

� � � �

� �

� � � � � � � � � �

� � � � � � �

� � � � �

�

� � � � � � � �

� � � �

�

� � � � �

� � � � � � � � �

��

� ��

��

�

��

� �

�

��

�

� ��

��

� � ��

� �

� � ��

��

� �

��

� ��

��

�

��

� ��

��

� �

�

��

�

��

� ��

� �

��

� �

��

� � ��

��

� �

��

� � ��

��

� ��

� �

��

� �

��

� ��

��

�

��

�

� �

�

��

� � � �

� �

� � � � �

�

� � � � �

��

��	�		��	�
��		�	�				�	��
��		��	��	�	�		�
		�		�	��	�	�
� ��	��	�	��	�	�		�
��	�	�	�	�	�
� ��	�	�	�		�		�	�
	�	�		�	�		�	�
��	��	��	�	�	��	�	�
��		�	��	�	�	�
��		��	�
��	��	�	�	�	��
		�
	��	�	�		��
� � ��	��	�		� ��	�	�
	��	��		�	�	�
��		��	�	��
��	�	�	�	��			�
			��				�	�
	��	�	�	�	�

								�
							�	�
							�
� � ��	�	�		�			�
��			��	�
	��	��	�	�	�	�
��	��	��	�	��	�
��		�	�	�	�		�
��	��	�		�		��	��
��	��	�	�				�
��	��	�	�
��		�	��	�

			�	�
�		�	�
�
			��
			��
			��
			��
		��
			��	��
		��
	��

��

Attachments

Original Link
Original Document
Permalink

Disclaimer

Suven Life Sciences Limited published this content on 23 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 November 2022 09:14:04 UTC.

Latest news about Suven Life Sciences Limited

Suven Life Sciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-06	CI
Suven Life Sciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-06	CI
Suven Life Sciences to Present Phase-2 Positive Results on Samelisant (SUVN-G3031) at American Academy of Neurology 2024 Annual Meeting, Denver, USA	04-15	CI
Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder Study in USA	02-06	CI
Suven Life Sciences Limited Approves the Retirement of Gopalakrishna Muddusetty as Non-Executive Independent Director, Effective March 31, 2024	01-30	CI
Suven Life Sciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	01-30	CI
Suven Life Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-04	CI
Suven Life Sciences Announces Positive Topline Results from A Phase-2 Study Evaluating Samelisant (SUVN-G3031) for Excessive Daytime Sleepiness in Adult Narcolepsy Patients with and Without Cataplexy	30/10/23	CI
Suven Pharma Appoints New Board and Management Team	29/09/23	CI
Suven Pharma Appoints Sudhir Kumar Singh as CEO	29/09/23	CI
Transcript : Suven Life Sciences Limited, Q1 2024 Earnings Call, Aug 10, 2023	10/08/23
Suven Life Sciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	08/08/23	CI
Suven Life Sciences Completes Enrollment of Patients to the Phase-2, Proof of Concept Clinical Study of Samelisant (SUVN-G3031) for the Treatment of Narcolepsy with or Without Cataplexy in USA and Canada	01/06/23	CI
Transcript : Suven Life Sciences Limited, Q4 2023 Earnings Call, May 26, 2023	25/05/23
Suven Life Sciences Limited Reports Earnings Results for the Full Year Ended March 31, 2023	09/05/23	CI
Suven Life Sciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	09/05/23	CI
Li & Fung considers options for $500 mln Asia healthcare arm, including a sale - sources	16/01/23	RE
Suven Life Sciences Limited Announces the Randomization of First Patient in the Phase-3 Global Clinical Trial of Masupirdine for the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type	16/11/22	CI
Suven Life Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	10/11/22	CI
Transcript : Suven Life Sciences Limited, Q2 2023 Earnings Call, Nov 09, 2022	09/11/22
Suven Pharmaceuticals' Consolidated Net Profit Declines in Fiscal Q2	08/11/22	MT
Suven Life Sciences Gets Board Panel Nod for Rights Issue	14/10/22	MT
Suven Pharmaceuticals Board Declares Interim Dividend and Special Dividend for Fiscal 2023	02/09/22	MT
Suven Life Sciences Limited Declares Special Dividend for the Financial Year 2022-23, Payable on and from September 20, 2022	02/09/22	CI
Suven Pharmaceuticals Mulls Interim Dividend for Fiscal 2023	29/08/22	MT

Chart Suven Life Sciences Limited

Duration

Period

More charts

Company Profile

Suven Life Sciences Limited is an India-based biopharmaceutical company. The Company is engaged in the drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. It operates through the research and development services segment. Its drug discovery & research/clinical pipeline include Masupirdine (SUVN-502) Neuropsychiatric Symptoms in Alzheimer's, Masupirdine (SUVN-502) Cognitive deficits in AD, Samelisant (SUVN-G3031) Narcolepsy, Samelisant (SUVN-G3031) Cognitive Disorders, Ropanicant (SUVN-911) Depressive Disorders, Usmarapride (SUVN-D4010), Cognitive Disorders, SUVN-I6107, Cognitive Disorders and Schizophrenia, SUVN-M8036, Psychiatric Disorders, and SUVN-D1044 Gastrointestinal Disorders. Its drug discovery & development support services (DDDSS) include synthetic and medicinal chemistry, analytical chemistry, in vitro biology, ADME, pharmacology, toxicology, bioanalysis, and NCE formulations.

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SUVEN LIFE SCIENCES LIMITED	+23.98%	262M
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+45.66%	40.65B
CELLTRION, INC.	-10.72%	27.12B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research